

THOMSON
DELPHION

RESEARCH PRODUCTS INSIDE DELPHION

Buy Now | New File | Search Searches | My Account | Products | Search: Advanced Search

The Delphion Integrated View

Buy Now: PDF | More choices...

Tools: [Citation Link](#) | Add to Work File: Create new Work

View: [Expand Details](#) | [INPADOC](#) | Jump to: [Top](#)


Go to: [Derwent](#)

Email

>Title: **US6063759: Conjugate of biologically active compound and polar lipid conjugated to a microparticle for biological targeting**
 [[Derwent Title](#)]

Country: US United States of America

Inventor: **Yatvin, Milton B.**; Portland, OR
Stowell, Michael H B; Fulbourn, United Kingdom
Gallicchio, Vincent S.; Lexington, KY
Meredith, Michael J.; Lake Oswego, OR



Assignee: **Oregon Health Sciences University**, Portland, OR
 other patents from **OREGON HEALTH SCIENCES UNIVERSITY**
 (420630) (approx. 161)
[News, Profiles, Stocks and More about this company](#)

Published / Filed: **2000-05-16 / 1998-04-14**

Application Number: **US1998000060011**

IPC Code: **A01N 37/18; A61K 9/127; A61K 47/00; C12N 5/08; C07K 17/00;**

ECLA Code: **C07H19/06E; C07H19/10E;**

U.S. Class: **514/002; 424/450; 435/176; 435/178; 435/179; 435/180; 435/325; 435/366; 530/300; 530/329; 530/331; 530/811; 530/813; 530/814; 530/815;**

Field of Search: **514/002 424/450 536/051,78,28.2 436/518,528
 530/300,331,329,810,815,811,813,814
 435/174,180,325,366,176,178,179**

Government Interest: This invention was made with government support under grant 1-R01-CA49416 by the National Institutes of Health. The government has certain rights in the invention.

Priority Number: **1998-04-14 US1998000060011
 1996-08-01 US1996000691891
 1995-05-16 US1995000441770
 1994-05-19 US1994000246941
 1993-10-26 US1993000142771
 1992-07-09 US1992000911209
 1990-11-01 US1990000607982**

Abstract: Methods and reagents are provided for specifically targeting biologically active compounds such as antiviral and antimicrobial drugs, or prodrugs containing the biologically active compound to specific sites such as specific organelles in phagocytic mammalian cells. The biologically active compound or prodrug is linked to a

microparticle with a linker that is non-specifically or specifically cleaved inside a phagocytic mammalian cell. Alternatively, the biologically active compound or prodrug is impregnated into a porous microparticle or coated on a nonporous microparticle, and then coated with a coating material that is non-specifically or specifically degraded inside a phagocytic mammalian cell. The prodrug contains the biologically active compound linked to a polar lipid such as ceramide with a specific linker such as a peptide that is specifically cleaved to activate the prodrug in a phagocytic mammalian cell infected with a microorganism. A microparticle linked antimicrobial drug or prodrug may be used for killing a microorganism infecting a phagocytic mammalian cell in vivo or in vitro.

❑ Attorney, Agent or Firm:

McDonnell Boehnen Hulbert & Berghoff ;

❑ Primary / Assistant Examiners:

Naff, David M.;

❑ INPADOC Legal Status:

None [Buy Now: Family Legal Status Report](#)

❑ Related Applications:

[Go to Result Set: 1 patent\(s\) that list this one as related](#)

Application Number	Filed	Patent	Pub. Date	Title
US1996000691891	1996-08-01	US5840674	1998-11-24	Covalent microparticle-drug conjugates for biological ta
US1995000441770	1995-05-16	US5543391	1996-08-06	Covalent microparticle-drug conjugates for biological ta
US1994000246941	1994-05-19	US5543390	1996-08-06	Covalent microparticle-drug conjugates for biological ta
US1993000142771	1993-10-26	US5543389	1996-08-06	Covalent polar lipid-peptide conjugates for use in salve
US1992000911209	1992-07-09	US5256641	1993-10-26	Covalent polar lipid-peptide conjugates for immunologic targeting
US1990000607982	1990-11-01	US5149794	1992-09-22	Covalent lipid-drug conjugates for drug targeting

❑ Parent Case:

This application is a continuation of application Ser. No. 08/691,891, filed Aug. 1, 1996, now U.S. Pat. No. 5,840,674, which is a continuation of application Ser. No. 08/441,770, filed May 16, 1995, now U.S. Pat. No. 5,543,391, which is a continuation of application Ser. No. 08/246,941, filed May 19, 1994, now U.S. Pat. No. 5,543,390, which is a continuation-in-part of application Ser. No. 08/142,771, filed Oct. 26, 1993, now U.S. Pat. No. 5,543,389, which is a continuation-in-part of application Ser. No. 07/911,209, filed Jul. 9, 1992, now U.S. Pat. No. 5,256,641, which is a continuation-in-part of application Ser. No. 07/607,982, filed Nov. 1, 1990, now U.S. Pat. No. 5,149,794, the disclosures of each of which are herein incorporated by reference in its entirety.

❑ Designated Country:

AM AP BB BG BR BY CA CN CZ EE FI GE HU IS KE KG KP KR KZ LK LR LT LV BE FR GB GR IE IT LI LU MC

Family: [Show 24 known family members](#)

First Claim: [Show all 69 claims](#)

What is claimed is:

1. A composition of matter comprising a prodrug of a biologically-active compound, a microparticle and a cleavable linker moiety comprising two linker functional groups, wherein the cleavable linker moiety has a first end and a second end and wherein the microparticle is attached to the first end of the linker moiety through a first linker functional group and the prodrug attached to the second end of the linker moiety through a second linker functional group, and wherein the cleavable linker moiety is non-specifically cleaved inside a phagocytic mammalian cell, and wherein the prodrug comprises a biologically active compound, a polar lipid moiety comprised of one or a plurality of polar lipid molecules and a specific linker moiety, wherein the specific linker moiety is covalently linked to both the biologically active compound and the polar lipid moiety, wherein the specific linker moiety is specifically cleaved in a phagocytic mammalian cell infected with a microorganism and is specifically activated thereby.

Background / Summary: [Show background / summary](#)

Drawing Descriptions:

Description: [Show description](#)

Forward References: [Show 2 U.S. patent\(s\) that reference this one](#)

U.S. References: [Go to Result Set: All U.S. references](#) | [Forward references \(2\)](#) | [Backward references](#) [Citation Link](#)

Buy PDF	Patent	Pub.Date	Inventor	Assignee	Title
	US4780455	1988-10	Liberman et al.	The Trustees of Columbia University in the City of New York	Lipophilic comp pharmacologica organic compou
	US4793986	1988-12	Serino et al.	Johnson Matthey, Inc.	Macromolecula antitumor comp
	US4847240	1989-07	Ryser et al.	The Trustees of Boston University	Method of effec uptake of molec
	US5053394	1991-10	Ellestad et al.	American Cyanamid Company	Targeted forms methyltrithio an agents
	US5149794	1992-09	Yatvin et al.	State of Oregon	Covalent lipid-d conjugates for d targeting
	US5256641	1993-10	Yatvin et al.	State of Oregon	Covalent polar peptide conjuga immunological t
	US5258453	1993-11	Kopecek et al.	University of Utah	Drug delivery sy the simultaneou of drugs activat enzymes and lig
				State of Oregon, Acting by and Through the Oregon State	Covalent polar

<input type="checkbox"/>	US5543389	1996-08	Yatvin et al.	Board of Higher Education on Behalf of the Oregon Health Sciences University, a non profit organization	peptide conjugates in salves
<input type="checkbox"/>	US5543390	1996-08	Yatvin et al.	State of Oregon, Acting by and Through the Oregon State Board of Higher Education, Acting for and on Behalf of the Oregon Health Sciences University	Covalent microp drug conjugates biological target
<input type="checkbox"/>	US5543391	1996-08	Yatvin et al.	State of Oregon, Acting by and Through the Oregon State Board of Higher Education, Acting for and on Behalf of the Oregon Health Sciences University	Covalent microp drug conjugates biological target
<input type="checkbox"/>	US5840674	1998-11	Yatvin et al.	Oregon Health Sciences University	Covalent microp drug conjugates biological target

Foreign References:

Buy PDF	Publication	Date	IPC Code	Assignee	Title
<input type="checkbox"/>	EP0077529	1983-04	C07C 93/187	Sanol Schwarz GmbH	Medicinal form
<input type="checkbox"/>	EP0109484	1983-04	G08B 21/00	Trampnau, Ulrich	Warning device for helicopters
<input type="checkbox"/>	EP0203676	1986-12	A61K 39/12	THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY	Vaccine for generating immunogenic response protein against a virus
<input type="checkbox"/>	EP0279887	1988-08	C07C 101/30	Kesner, Leo	Carnitine direct pharmaceuticals and their use for manufacture of medicament for treatment of metabolic disorder
<input type="checkbox"/>	WO8911299	1989-11	A61K 49/00	STATE OF OREGON acting by and through THE STATE ...	METHOD FOR DELIVERY OF THERAPEUTIC AGENTS TO TARGET TISSUE USING MONOCLONAL ANTIBODY CONJUGATES
<input type="checkbox"/>	WO8910348	1989-11	C07C 99/10	GIBBONS, William, Anthony	FATTY AMINO ACIDS AND HOMO-A HETERO-OLIGOMERIC CONJUGATES THEREOF
<input type="checkbox"/>	WO9000555	1990-01	C07H 15/12	VICAL, INC.	LIPID DERIVATIVES ANTIVIRAL NUCLEOSIDE LIPOSOMAL INCORPORATION METHOD OF COVALENT CONJUGATES

<input checked="" type="checkbox"/>	<u>WO9010448</u>	1990-09	A61K 31/70	GENENTECH, INC.	<u>AND OLIGONUCLE</u> <u>LIPID A</u> <u>ANALOG/IMM</u> <u>CARRIER CO</u> <u>AND THE USE</u> <u>AS VACCINES</u>
<input checked="" type="checkbox"/>	<u>WO9101750</u>	1991-02	A61K 39/02	UNIVAX BIOLOGICS INCORPORATED	<u>CATIONIC LIP</u> <u>INTRACELLU</u> <u>DELIVERY OF</u> <u>BIOLOGICALL</u> <u>MOLECULES</u>
<input checked="" type="checkbox"/>	<u>WO9116024</u>	1991-10	A61F 13/00	VICAL, INC.	<u>ETHER LIPID-</u> <u>NUCLEOSIDE</u> <u>COVALENT</u> <u>CONJUGATES</u>
	<u>WO9119726A</u>	1991-12	C07H 17/00	KUCERA, Louis, S.	<u>TRANSVASCU</u> <u>INTRACELLU</u> <u>DELIVERY OF</u> <u>PROTEINS</u>
<input checked="" type="checkbox"/>	<u>WO9401131</u>	1994-01	A61K 39/00	EUKARION, INC.	<u>COVALENT P</u> <u>LIPID-PEPTID</u> <u>CONJUGATES</u> <u>BIOLOGICAL</u> <u>TARGETING</u>
<input checked="" type="checkbox"/>	<u>WO9401138</u>	1994-01	A61K 47/48	STATE OF OREGON, acting by and through the OREGON STATE BOARD OF HIGHER EDUCATION on behalf of the OREGON HEALTH SCIENCES UNIVERSITY	<u>TARGETING O</u> <u>LIPOSOMES T</u> <u>BLOOD-BRAIN</u> <u>BARRIER</u>
<input checked="" type="checkbox"/>	<u>WO9402178</u>	1994-02	A61K 47/48	THE GOVERNMENT OF THE UNITED STATES OF AMERICA as	<u>COMPOUND</u> <u>OF INTRACER</u> <u>RESIDENCE A</u> <u>THEREOF</u>
<input checked="" type="checkbox"/>	<u>WO9403424</u>	1994-02	C07C 323/41	DRUG DELIVERY SYSTEM INSTITUTE, LTD.	<u>BRAIN-ENHAN</u> <u>DELIVERY OF</u> <u>NEUROACTIV</u> <u>PEPTIDES BY</u> <u>SEQUENTIAL</u> <u>METABOLISM</u>
<input checked="" type="checkbox"/>	<u>WO9406450</u>	1994-03	A61K 37/00	UNIVERSTIY OF FLORIDA	<u>CELL-TARGE</u> <u>PORE-FORMI</u> <u>AGENTS</u>
<input checked="" type="checkbox"/>	<u>WO9425616</u>	1994-11	C12P 21/00	WORCESTER FOUNDATION FOR EXPERIMENTAL BIOLOGY	<u>BLOOD-BRAIN</u> <u>TRANSPORTE</u> <u>NEUROLOGIC</u> <u>AGENTS</u>
<input checked="" type="checkbox"/>	<u>WO9507092</u>	1995-03	A61K 38/00	THE UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JE	<u>DRUG TARGE</u> <u>SYSTEM, MET</u> <u>PREPARINGS</u> <u>ITS USE</u>
<input checked="" type="checkbox"/>	<u>WO9522963</u>	1995-08	A61K 9/51	MEDINOVA MEDICAL CONSULTING GMBH	<u>COVALENT</u> <u>MICROPARTI</u> <u>CONJUGATES</u> <u>BIOLOGICAL</u> <u>TARGETING</u>
<input checked="" type="checkbox"/>	<u>WO9532002</u>	1995-11	A61K 47/48	STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE OREGON HEALTH	

				SCIENCES UNIVERSITY	
	WO9604001	1996-02	A61K 38/00	MOLECULAR/STRUCTURAL BIOTECHNOLOGIES, INC.	SITE-SPECIFI BIOMOLECUL COMPLEXES
	WO9622303	1996-07	C07J 5/00	BENDER, Veronika, Judith	THERAPEUTI COMPOUND ACID CONJUG

Other Abstract Info: CHEMABS 118(04)027456V CHEMABS 120(24)307470P CHEMABS 124(14)185548E 125(16)204546S CHEMABS 125(18)230787R CHEMABS 129(25)335730C DERABS C 340298 DERABS C1993-350862 DERABS C1996-020359

Other References:

- Abbas et al., "Antigen Presentation and T Cell Antigen Recognition," *Cellular* as J. Mo (W.B. Saunders Co.; Philadelphia), pp. 116-136.
- Afzelius et al., *Biochim. Biophys. Acta* 979: 231-238 (1989).
- Alvarez-Dominquez et al., "Role of Complement Component C1q in Phagocytosis of *L* monocytogenes by Murine Macrophage-Like Cell Lines," *Infect. Immun.* 61:3664-3672 (1993).
- Anderson et al., *J. Am. Chem. Soc.* 85: 3039 (1963).
- Ashborn et al., "Anti-HIV Activity of CD4-Pseudomonas Exotoxin on Infected Primary Lymphocytes and Monocyte/Macrophages," *J. Infect. Dis.* 163: 703-709 (1991).
- Baer, *Can. J. Biochem. Phys.* 34: 288-304 (1955).
- Bai and Amidon, "Structural Specificity of Mucosal-Cell Transport and Metabolism of P Drugs: Implications for Oral Peptide Drug Delivery," *Pharm. Res.* 9: 969-978 (1992).
- Bai et al., "Utilization of Peptide Carrier System to Improve Intestinal Absorption: Targ Prolidase as a Prodrug-Converting Enzyme," *J. Pharm. Sci.* 81: 113-116 (1992).
- Barlow et al., "Mast cells and T lymphocytes in chronic urticaria," *Clinical & Experimental Allergy* 25: 317-322 (1995).
- Baroni et al., "Expression of HIV in Lymph Node Cells of LAS Patients: Immunohistochemical Hybridization, and Identification of Target Cells," *Am. J. Pathol.* 133: 498-506 (1988).
- Berdel et al., *Lipids* 22: 943-946 (1987).
- Bickel et al., "Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery," *Proc. Natl. Acad. Sci. USA* 90: 2618-2622 (1993).
- Blakey, "Drug Targeting with Monoclonal Antibodies," *Acta Oncol.* 31: 91-97 (1992).
- Blight et al., "Detection of hepatitis C virus RNA by in situ hybridization," *Liver* 12: 286.
- Blum et al., "Blood clearance and organ deposition of intravenously administered colloid particles: the effects of particle size, nature and shape," *Int. J. Pharm.* 12: 135-146 (1982).
- Boehnlein et al., "Characterization of Esterase and Alcohol Dehydrogenase Activity in the Metabolism of Retinyl Palmitate to Retinol (Vitamin A) During Percutaneous Absorption," *Pharmaceutical Research* 11: 1155-1159 (1994).
- Boman et al., "Cell-free immunity in *Cecropia*: A model system for antibacterial protein," *Biochem.* 201: 23-31 (1990).
- Borissova et al., "Biodegradable Microspheres. 17. Lysosomal Degradation of Primärarm Spacer Arms," *Journal of Pharmaceutical Sciences*, vol. 84, No. 2, Feb. 1995, pp. 256-262.
- Bou-Gharios et al., "Expression of ectopeptidases in scleroderma," *Annals of Rheumatology Disease* 54: 111-116 (1995).
- Brewster et al., "Improved Delivery through Biological Membranes XXXI: Solubilization and Stabilization of an Estradiol Chemical Delivery System by Modified β -Cyclodextrins," *J. Pharm. Sci.* 77: 981-985 (1985).
- Bromberg et al., "Detection of *Bordetella pertussis* Associated with the Alveolar Macrophages in Children with Human Immunodeficiency Virus Infection," *Infect. Immun.* 59: 4715-4719 (1991).
- Brown & Silvius, *Biochim. Biophys. Acta* 1023: 341-351 (1990).
- Brown et al., "Induction of Cell Surface Peptidase Activity: A Global Response to Cell Correlated with Apoptosis," *J. Cellular Biochemistry* 54: 320-331 (1994).
- Brynestad et al., *J. Virol.* 64:680-685 (1990).

- Buchmeier and Heffron, "Induction of *Salmonella* Stress Proteins upon Infection of *Macrophages*," *Science* 248: 730-732 (1990).
- Buyuktimkin et al., "Synthesis and Enhancing Effect of Dodecyl 2-(N,N-Dimethylamino) on the Transepidermal Delivery of Indomethacin, Clonidine, and Hydrocortisone," *Pharm Research* 10: 1632-1637 (1993).
- Chang, "Leishmania donovani: Promastigote-Macrophage Surface Interactions in *Vitr* *Parasitol*." 48:175-189 (1979).
- Clarke et al., "Detection of HIV-1 in human lung macrophages using the polymerase c reaction," *AIDS* 4: 1133-1136 (1990).
- Comiskey & Heath, *Biochim. Biophys. Acta* 1024: 307-317 (1990).
- Cordier et al., "In vivo Activation of Alveolar Macrophages in Ovine Lentivirus Infection," *Immunol. Immunopathol.* 55: 355-367 (1990).
- Couveur and Puisieux, "Nano-and microparticles for the delivery of polypeptides and *peptides*," *Adv. Drug Deliv. Rev.* 10: 141-162 (1993).
- Dachun et al., "Localization and Quantification of the Nonspecific Esterase in Injured *Skin* Cells," *Forensic Science International* 53: 203-213 (1992).
- De Magistris et al., "Antigen Analog-Major Histocompatibility Complexes Act As Antagonists of the T Cell Receptor," *Cell* 68: 625-634 (1992).
- Debs et al., *Biochim. Biophys. Acta* 901: 183-190 (1987).
- Deres et al., *Nature* 342:561-564 (1989).
- Dreyer et al., *Proc. Natl. Acad. Sci. USA* 86: 9752-9756 (1989).
- Duncan, "Drug-polymer conjugates: potential for improved chemotherapy," *Anticancer Res.* 12: 175-210 (1992).
- Elliott et al., "Naturally processed peptides," *Nature* 348: 195-197 (1990).
- Embretson et al., "Massive covert infection of helper T lymphocytes and macrophage during the incubation period of AIDS," *Nature* 362: 359-361 (1993).
- Falk et al., "Allele-specific motifs revealed by sequencing of self-peptides eluted from molecules," *Nature* 351: 290-291 (1991).
- Falk et al., "Cellular peptide composition governed by major histocompatibility complex molecules," *Nature* 348: 248-251 (1990).
- Faulk et al., "Transferrin-Adriamycin Conjugates which Inhibit Tumor Cell Proliferation," *Interaction with DNA Inhibit Plasma Membrane Oxidoreductase and Proton Release in *K562* Cells*," *Biochem. Int.* 25: 815-822 (1991).
- Faustman et al., "Linkage of Faulty Major Histocompatibility Complex Class I to Autoimmunity in *Diabetes*," *Science* 254: 1756-1776 (1991).
- Franssen et al., "Low Molecular Weight Proteins as Carrier for Renal Drug Targeting: of Drug-Protein Conjugates and Drug-Spacer Derivatives and Their Catabolism in Renal Homogenates and Lysosomal Lysates," *J. Med. Chem.* 35: 1246-1259 (1992).
- Frehel et al., "Intramacrophage Growth of *Mycobacterium avium* during Infection of *Mice*," *Immunol. Rev.* 150: 2207-2214 (1991).
- Friedman et al., "Uptake and Intracellular Survival of *Bordetella pertussis* in Human Macrophages," *Infect. Immun.* 60: 4578-4585 (1992).
- Frisch et al., "Parameters affecting the immunogenicity of a liposome-associated synthetic hexapeptide antigen," *Eur. J. Immunol.* 21: 185-193 (1991).
- Gaspar et al., "Drug targeting with polyalkylcyanoacrylate nanoparticles: in vitro activation of primaquine-loaded nanoparticles against intracellular *Leishmania donovani*," *Ann. Trop. Parasitol.* 86: 41-49 (1992).
- Gendelman et al., "Slow, persistent replication of lentiviruses: Role of tissue macrophages and macrophage precursors in bone marrow," *Proc. Natl. Acad. Sci. USA* 82: 7086-7090 (1985).
- Germain & Hendrix, "MHC class II structure, occupancy and surface expression determine post-endoplasmic reticulum antigen binding," *Nature* 353: 134-139 (1991).
- Groisman et al., "Resistance to host antimicrobial peptides is necessary for *Salmonella* infection," *Proc. Natl. Acad. Sci. USA* 89: 11939-11943 (1992).
- Guery et al., "Selective Immunosuppression by Administration of Major Histocompatibility Complex (MHC) Class II-binding Peptides. I. Evidence for In Vivo MHC Blockade Prevention of *Leishmania donovani* Infection," *Science* 261: 121-124 (1993).


Activation," *J. Exp. Med.* 175: 1345-1352 (1992).

- Halstead et al., "Dengue Viruses and Mononuclear Phagocytes: I. Infection Enhancement by Neutralizing Antibody," *J. Exp. Med.* 146:201-217 (1977).
- Hashimoto et al., *Biochim. Biophys. Acta* 816: 163-168 (1985).
- Hashimoto et al., *Biochim. Biophys. Acta* 816: 169-178 (1985).
- Heath and Martin, *Chem. Phys. Lipids* 40: 347-358 (1986).
- Heath et al., *Biochim. Biophys. Acta* 862: 72-80 (1986).
- Heath, *Methods in Enzymol.* 149: 111-119.
- Heinrich et al., "In-vivo Release of a GnRH Agonist from a Slow-release Poly(lactide-g Copolymer Preparation: Comparison in Rat, Rabbit and Guinea-Pig," *J. Pharm. Pharmacol.* 765 (1991).
- Henrikus and Kampffmeyer, "Ester hydrolysis conjugation reactions in intact skin and homogenate, and by liver esterase of rabbits," *Xenobiotica* 22: 1357-1366 (1992).
- Heymann et al., "Organophosphate Sensitive and Insensitive Carboxylesterases in Human Chem. Biol. Interactions 87: 217-226 (1993).
- Hopp, "Immunogenicity of a Synthetic HBsAg Peptide: Enhancement by Conjugation to an Acid Carrier," *Mol. Immunol.* 21: 13-16 (1984).
- Horwitz and Maxfield, "Legionella pneumophila Inhibits Acidification of its Phagosome in Monocytes," *J. Cell Biol.* 99: 1936-1943 (1984).
- Horwitz, "Interactions between Macrophages and Legionella pneumophila," *Curr. Top. Immunol.* 181:265-282 (1992).
- Horwitz, "The Legionnaires' Disease Bacterium (Legionella pneumophila) Inhibits Phagosome Lysosome Fusion in Human Monocytes," *J. Exp. Med.* 158: 2108-2126 (1983).
- Hostetler et al., *J. Biol. Chem.* 265: 6112-6117 (1990).
- Hunter et al., "Vesicular Systems (Niosomes and Liposomes) for Delivery of Sodium Stibogluconate in Experimental Murine Visceral Leishmaniasis," *J. Pharm. Pharmacol.* 40 (1988).
- Jacobson et al., *FEBS Lett.* 225: 97-102 (1987).
- Jardetzky et al., "Identification of self peptides bound to purified HLA-B27," *Nature* 35 (1991).
- Jones and Hirsch, "The Interaction between Toxoplasma gondii and Mammalian Cells," *Med.*, 136:1173-1194 (1972).
- Kanno et al., "Aleutian Mink Disease Parvovirus Infection of Mink Peritoneal Macrophages and Human Macrophage Cell Lines," *J. Virol.* 67:2075-2082.
- Kanno et al., "Identification of Aleutian Mink Disease Parvovirus Transcripts in Macroparasites of Adult Mink," *J. Virol.* 66:5305-5312 (1992).
- King et al., "In Vivo Selection of Lymphocyte-Tropic and Macrophage-Tropic Variants of Lymphocytic Choriomeningitis Virus during Persistent Infection," *J. Virol.* 64: 5611-5616 (1990).
- Kinsky & Loeder, *Biochim. Biophys. Acta* 921: 96-103 (1987).
- Kinsky et al., *Biochim. Biophys. Acta* 885: 129-135 (1986).
- Kinsky et al., *Biochim. Biophys. Acta* 917: 211-218 (1987).
- Kishimoto, *Chem. Phys. Lipids* 15: 33-36 (1975).
- Koenig et al., "Detection of AIDS Virus in Macrophages in Brain Tissue from AIDS Patients," *Science* 233: 1089-1093 (1986).
- Kondo et al., "Latent human herpesvirus 6 infection of human monocytes/macrophage," *J. Virol.* 72: 1401-1408 (1991).
- Koval & Pagano, "Lipid Recycling between the Plasma Membrane and Intracellular Compartments: Transport and Metabolism of Fluorescent Sphingomyelin Analogues in C3H10T1/2 Fibroblasts," *J. Cell Biol.* 108: 2169-2181 (1989).
- Kratz et al., "Keratinocyte conditioned medium stimulates type IV collagenase synthesis in cultured human keratinocytes and fibroblasts," *Brit. J. Dermatology* 133: 842-846 (1995).
- Kreeger, *The Scientist*, Sep. 16, 1996, p. 6.
- Krowka et al., *J. Immunol.* 144: 2535-2540 (1990).
- Kubota et al., "Metabolism and Degradation of Betamethasone 17-Valerate in Homograft Living Skin Equivalent," *Dermatology* 188: 13-17 (1994).

- Kung and Redemann, *Biochim. Biophys. Acta* 862: 435-439 (1986).
- Lamont et al., "The use of Peptide Analogs with Improved Stability and MHC Binding Inhibit Antigen Presentation In Vitro and In Vivo," *J. Immunol.* 144: 2493-2498 (1990).
- Lanzavecchia et al., "Irreversible association of peptides with class II MHC molecules cells," *Nature* 357: 249-252 (1992).
- Larsen et al., "Stability of ketoprofen-dextran ester prodrugs in homogenates of various of the pig GI tract," *Acta Pharm. Nord.* 3: 41-44 (1991).
- Lee et al., "Antibacterial peptides from pig intestines: Isolation of a mammalian cecropin," *Natl. Acad. Sci. USA* 86: 9159-9162 (1989).
- Lehninger, *Biochemistry*, 2d ed., Chapters 11 & 24, Worth Publishers: New York, 1973.
- Lehrer et al., "Defensins: Endogenous Antibiotic Peptides of Animal Cells," *Cell* 64: 22 (1991).
- Lin et al., "Preparation of Enteric-Coated Microspheres of mycoplasma hyopneumoniae cellulose acetate; (ii) effect of temperature and pH on the stability and release behaviour microspheres," *Journal of Microencapsulation*, vol. 8, No. 4: 537-545 (1991).
- Lipozencic et al., "Langerhans cells in the immunopathology of contact allergic dermatitis," *Histochem* 38: 303-310 (1994).
- Loughery et al., *J. Immunol. Methods* 132: 25-35 (1990).
- MacDonald, *J. Biol. Chem.* 265: 13533-13539 (1990).
- Maciejewski et al., "Infection of Mononucleated Phagocytes with Human Cytomegalovirus," *Journal of Microbiology* 195: 327-336 (1993).
- Matsura et al., *J. Chem. Soc. Chem. Comm.* xx: 451-459 (1976).
- Mauel et al., "Quantitative Release of Live Micro-organisms from Infected Macrophages," *Nature New Biol.* 244: 93-94 (1973).
- Mauel, "Macrophage-Parasite Interactions in Leishmania Infections," *J. Leukocyte Biology* 193 (1990).
- McEntee et al., "Rhesus monkey macrophages infected with simian immunodeficiency virus cause rapid lysis of CD4-bearing lymphocytes," *J. Gen. Virol.* 72: 317-324 (1991).
- Meltzer and Gendelman, "Mononuclear Phagocytes as Targets, Tissue Reservoirs, and Immunoregulatory Cells in Human Immunodeficiency Virus Disease," *Curr. Topics Microbiol. Immunol.* 181: 239-263 (1992).
- Menger et al., "Synthesis of a Lipid/Peptide/Drug Conjugate: N4-(Acylpeptidyl)-ARA-C Bioconjugate Chemistry 5: 162-166 (1994).
- Moehrle et al., "Aminopeptidase M and dipeptidyl peptidase IV activity in epithelial skin histochemical study," *J. Cutaneous Pathology* 22: 241-247 (1995).
- Mukherjee & Heidelberger, *Cancer Res.* 22: 815-822 (1962).
- Murray et al., "Experimental Visceral Leishmaniasis: Production of Interleukin 2 and In Tissue Immune Reaction, and Response to Treatment with Interleukin 2 and Interferon gamma," *Journal of Immunology* 138: 2290-2296 (1987).
- Narayan et al., "Lentivirus Induced Arthritis in Animals," *J. Rheumatol.* 32: 25-32 (1992).
- Negre et al., "Antileishmanial Drug Targeting through Glycosylated Polymers Specific Internalized by Macrophage Membrane Lectins," *Antimicrob. Agents and Chemother.* 36 (1992).
- Neto et al., *Biochem. Biophys. Res. Commun.* 171: 458-464 (1990).
- Ng & Heath, *Biochim. Biophys. Acta* 981: 261-268 (1989).
- Nogueira and Cohn, "Trypanosoma cruzi: Mechanisms of Entry and Intracellular Fate in Mammalian Cells," *J. Exp. Med.* 143: 1402-1420 (1976).
- Nothnagel, *Biochim. Biophys. Acta* 980: 209-219 (1989).
- Pagano et al., *J. Biol. Chem.* 258: 2034-2040 (1983).
- Panuska et al., "Productive Infection of Isolated Human Alveolar Macrophages by Respiratory Syncytial Virus," *J. Clin. Invest.* 86: 113-119 (1990).
- Pardridge, "Opioid Peptide Drug Development: Transport of Opioid Chimeric Peptides Across the Blood-Brain Barrier," *NIDA Res. Monograph* 120: 153-168 (1992).
- Parham, "Transporters of delight," *Nature* 348: 674-675 (1990).
- Paul and Anderson, *J. Am. Chem. Soc.* 82: 4596-4600 (1960).

- Payne et al., "Phagocytosis of *Legionella pneumophila* is Mediated by Human Monoc Complement Receptors," *J. Exp. Med.* 166: 1377-1389 (1987).
- Rahman et al., *Life Sci.* 31: 2061-2071 (1982).
- Remy et al., *J. Org. Chem.* 27: 2491-2500 (1962).
- Rosenberg et al., *J. Neurochem.* 48: 865-875 (1987).
- Rowlinson-Busza and Epenetos, "Targeted delivery of biologic and other antineoplast *Curr. Opin. Oncol.* 4: 1142-1148 (1992).
- Rubinstein et al., "In Vitro Evaluation of Calcium Pectinate: A Potential Colon-Specific Delivery Carrier," *Pharm. Res.* 10: 258-263 (1993).
- Sadegh-Nasseri and Germain, "A role for peptide in determining MHC class II structur 353: 167-170 (1991).
- Saffran et al., "A New Approach to the Oral Administration of Insulin and Other Peptid *Science* 233: 1081-1084 (1986).
- Salord et al., *Biochim. Biophys. Acta* 886: 64-75 (1986).
- Schlessinger and Horwitz, "Phagocytosis of Leprosy Bacilli is Mediated by Compleme Receptors CR1 and CR3 on Human Monocytes and Complement Component C3 in Ser *Invest.* 85: 1304-1314 (1990).
- Schmitt et al., "Multiplication of Human Immunodeficiency Virus in Primary Cultures o Kupffer Cells—Possible Role of Liver Macrophage Infection in the Physiopathology of AIDS *Virol.* 141: 143-152 (1990).
- Schnorr et al., "MxA-Dependent Inhibition of Measles Virus Glycoprotein Synthesis in Transfected Human Monocytic Cell Line," *J. Virol.* 67: 4760-4768 (1993).
- Seifert et al., *Biochem. J.* 267:795-802 (1990).
- Sellon et al., "Wild-Type Equine Infectious Anemia Virus Replicates in Vivo Predomin Tissue Macrophages, Not in Peripheral Blood Monocytes," *J. Virol.* 66: 5906-5913 (1992).
- Senter et al., "Activation of Prodrugs by Antibody-Enzyme Conjugates," in *Immunobio Peptides and Proteins*, vol. VI, pp. 97-105 (1991).
- Shanley and Pesanti, "Murine Peritoneal Macrophages Support Murine Cytomegalovi Replication," *Infect. Immunol.* 41: 1352-1359 (1983).
- Shen et al., "Cis-Aconityl Spacer between Daunomycin and Macromolecular Carriers: pH Sensitive Linkage Releasing Drug from a Lysomotropic Conjugate," *Biochem. Biophys Commun.* 102:1048-1052 (1981).
- Sierra-Honigman et al., "Borna disease virus in peripheral blood mononuclear and bo cells of neonatally and chronically infected rats," *J. Neuroimmunol.* 45: 31-36 (1993).
- Sintov et al., "Enzymatic cleavage of disaccharide side groups in insoluble synthetic new method for specific delivery of drugs to the colon," *Biomaterials* 14: 483-490 (1993).
- SivaSai et al., "Effect of Recombinant Interferon Gamma Administration on Lesional Monocytes/Macrophages in Lepromatous Leprosy Patients," *Int. J. Leprosy & Other Myc Diseases* 61: 259-269 (1993).
- Small, "From alkanes to phospholipids," *Handbook of Lipid Research: Physical Chem Lipids*, vol. 4, Chapters 4 and 12, Plenum Press: New York, 1986.
- Smith and Khorana, *J. Amer. Chem. Soc.* 80: 1141-1145 (1958).
- Steim et al., *Biochem. Biophys. Res. Commun.* 171: 451-457 (1990).
- Strellrecht-Broomhall, "Evidence for Immune-Mediated Destruction as Mechanism for Induced Anemia in Persistently Infected Mice," *Viral Immunol.* 4: 269-280 (1991).
- Sturgill-Koszycki et al., "Lack of Acidification in *Mycobacterium* Phagosomes Produce Exclusion of the Vesicular Proton-ATPase," *Science* 263: 678-681 (1994).
- Trouet et al., "A covalent linkage between daunorubicin and proteins that is stable in s reversible by lysosomal hydrolases, as required for a lysomotropic drug-carrier conjugate and in vivo studies," *Proc. Natl. Acad. Sci. USA* 79:626-629 (1982).
- van Wijk et al., *Biochim. Biophys. Acta* 1084: 307-310 (1991).
- Vandenberg et al., *Nature* 341:841-844 (1989).
- Verbloom et al., *Synthesis* 1032: 807-809 (1981).
- Wada et al., "Salt Formation of Lactic Acid Oligomers as Matrix for Sustained Release *J. Pharm. Pharmacol.* 43: 605-608 (1991).

- Wiesmuller et al., "The antibody response in BALB/c mice to the Plasmodium falciparum circumsporozoite repetitive epitope covalently coupled to synthetic lipopeptide adjuvant," 109-113 (1991).
- Wyrick and Brownridge, "Growth of Chlamydia psittaci in Macrophages," Infect. Immun. 19:1054-1060 (1978).
- Yatvin et al., "Targeting Lipophilic Prodrugs to Brain, Lung, and Spleen," Journal of Cell Biochemistry, vol. 0, No. 19A: 173 (1995).
- Yatvin, "A Multi-Modality Approach for the Treatment of AIDS," Select. Cancer. Ther. 28 (1991).
- Zasloff, "Magainins, a class of antimicrobial peptides from *Xenopus* skin: Isolation, characterization of two active forms, and partial cDNA sequence of a precursor," Proc. Natl. Acad. Sci. USA 84: 5449-5453 (1987).
- Zhang and McCormick, "Uptake of N-(4'-pyridoxyl)amines and release of amines by a model for transporter-enhanced delivery of bioactive compounds," Proc. Natl. Acad. Sci. 10407-10410 (1991).



Nominate this for the Galle

© 1997-2003 Thomson Delphion [Research Subscriptions](#) | [Privacy Policy](#) | [Terms & Conditions](#) | [Site Map](#) | [Contact Us](#) | [Help](#)



RESEARCH

PRODUCTS

INSIDE DELPHION

[Login](#) | [New File](#) | [Search](#) | [Advanced Search](#) | [Help](#) | [Feedback](#) | [Privacy](#)
[Search](#) | [Buckets](#) | [Clipboard](#) | [Recent](#) | [Help](#) | [Logout](#)


The Delphion Integrated View

Buy Now: [PDF](#) | [More choices...](#)Tools: [Citation Link](#) | [Add to Work File](#): [Create new Work](#)View: [Expand Details](#) | [INPADOC](#) | Jump to: [Top](#)
[Go to:](#) [Derwent](#)
[Email](#)

>Title: **US6063759: Conjugate of biologically active compound and polar lipid conjugated to a microparticle for biological targeting**
 [[Derwent Title](#)]

Country: **US United States of America**

Inventor: **Yatvin, Milton B.; Portland, OR**
Stowell, Michael H B; Fulbourn, United Kingdom
Gallicchio, Vincent S.; Lexington, KY
Meredith, Michael J.; Lake Oswego, OR



Assignee: **Oregon Health Sciences University, Portland, OR**
 other patents from [OREGON HEALTH SCIENCES UNIVERSITY \(420630\)](#) (approx. 161)
[News, Profiles, Stocks and More about this company](#)

Published / Filed: **2000-05-16 / 1998-04-14**

Application Number: **US1998000060011**

IPC Code: **A01N 37/18; A61K 9/127; A61K 47/00; C12N 5/08; C07K 17/00;**

ECLA Code: **C07H19/06E; C07H19/10E;**

U.S. Class: **514/002; 424/450; 435/176; 435/178; 435/179; 435/180; 435/325; 435/366; 530/300; 530/329; 530/331; 530/811; 530/813; 530/814; 530/815;**

Field of Search: **514/002 424/450 536/051,78,28.2 436/518,528
 530/300,331,329,810,815,811,813,814
 435/174,180,325,366,176,178,179**

Government Interest: This invention was made with government support under grant 1-R01-CA49416 by the National Institutes of Health. The government has certain rights in the invention.

Priority Number: **1998-04-14 US1998000060011
 1996-08-01 US1996000691891
 1995-05-16 US1995000441770
 1994-05-19 US1994000246941
 1993-10-26 US1993000142771
 1992-07-09 US1992000911209
 1990-11-01 US1990000607982**

Abstract: Methods and reagents are provided for specifically targeting biologically active compounds such as antiviral and antimicrobial drugs, or prodrugs containing the biologically active compound to specific sites such as specific organelles in phagocytic mammalian cells. The biologically active compound or prodrug is linked to a

microparticle with a linker that is non-specifically or specifically cleaved inside a phagocytic mammalian cell. Alternatively, the biologically active compound or prodrug is impregnated into a porous microparticle or coated on a nonporous microparticle, and then coated with a coating material that is non-specifically or specifically degraded inside a phagocytic mammalian cell. The prodrug contains the biologically active compound linked to a polar lipid such as ceramide with a specific linker such as a peptide that is specifically cleaved to activate the prodrug in a phagocytic mammalian cell infected with a microorganism. A microparticle linked antimicrobial drug or prodrug may be used for killing a microorganism infecting a phagocytic mammalian cell in vivo or in vitro.

⑧ Attorney, Agent or Firm:

McDonnell Boehnen Hulbert & Berghoff ;

⑧ Primary / Assistant Examiners:

Naff, David M.;

⑧ INPADOC

Legal Status: None [Buy Now: Family Legal Status Report](#)

⑧ Related Applications:

[Go to Result Set: 1 patent\(s\) that list this one as related](#)

Application Number	Filed	Patent	Pub. Date	Title
US1996000691891	1996-08-01	US5840674	1998-11-24	Covalent microparticle-drug conjugates for biological ta
US1995000441770	1995-05-16	US5543391	1996-08-06	Covalent microparticle-drug conjugates for biological ta
US1994000246941	1994-05-19	US5543390	1996-08-06	Covalent microparticle-drug conjugates for biological ta
US1993000142771	1993-10-26	US5543389	1996-08-06	Covalent polar lipid-peptide conjugates for use in salve
US1992000911209	1992-07-09	US5256641	1993-10-26	Covalent polar lipid-peptide conjugates for immunologic targeting
US1990000607982	1990-11-01	US5149794	1992-09-22	Covalent lipid-drug conjugates for drug targeting

⑧ Parent Case:

This application is a continuation of application Ser. No. 08/691,891, filed Aug. 1, 1996, now U.S. Pat. No. [5,840,674](#), which is a continuation of application Ser. No. 08/441,770, filed May 16, 1995, now U.S. Pat. No. [5,543,391](#), which is a continuation of application Ser. No. 08/246,941, filed May 19, 1994, now U.S. Pat. No. [5,543,390](#), which is a continuation-in-part of application Ser. No. 08/142,771, filed Oct. 26, 1993, now U.S. Pat. No. [5,543,389](#), which is a continuation-in-part of application Ser. No. 07/911,209, filed Jul. 9, 1992, now U.S. Pat. No. [5,256,641](#), which is a continuation-in-part of application Ser. No. 07/607,982, filed Nov. 1, 1990, now U.S. Pat. No. [5,149,794](#), the disclosures of each of which are herein incorporated by reference in its entirety.

⑧ Designated Country:

AM AP BB BG BR BY CA CN CZ EE FI GE HU IS KE KG KP KR KZ LK LR LT LV BE FR GB GR IE IT LI LU MC

Family: [Show 24 known family members](#)

First Claim: [Show all 69 claims](#)

What is claimed is:

1. A composition of matter comprising a prodrug of a biologically-active compound, a microparticle and a cleavable linker moiety comprising two linker functional groups, wherein the cleavable linker moiety has a first end and a second end and wherein the microparticle is attached to the first end of the linker moiety through a first linker functional group and the prodrug attached to the second end of the linker moiety through a second linker functional group, and wherein the cleavable linker moiety is non-specifically cleaved inside a phagocytic mammalian cell, and wherein the prodrug comprises a biologically active compound, a polar lipid moiety comprised of one or a plurality of polar lipid molecules and a specific linker moiety, wherein the specific linker moiety is covalently linked to both the biologically active compound and the polar lipid moiety, wherein the specific linker moiety is specifically cleaved in a phagocytic mammalian cell infected with a microorganism and is specifically activated thereby.

Background / [Show background / summary](#)

Summary:

Drawing

Descriptions:

Description:

Forward

References:

[Show 2 U.S. patent\(s\) that reference this one](#)

U.S. References: [Go to Result Set: All U.S. references](#) | [Forward references \(2\)](#) | [Backward references](#)
[Citation Link](#)

Buy PDF	Patent	Pub.Date	Inventor	Assignee	Title
	US4780455	1988-10	Liberman et al.	The Trustees of Columbia University in the City of New York	Lipophilic comp pharmacologica organic compou
	US4793986	1988-12	Serino et al.	Johnson Matthey, Inc.	Macromolecula antitumor comp
	US4847240	1989-07	Ryser et al.	The Trustees of Boston University	Method of effec uptake of molec
	US5053394	1991-10	Ellestad et al.	American Cyanamid Company	Targeted forms methyltrithio an agents
	US5149794	1992-09	Yatvin et al.	State of Oregon	Covalent lipid-d conjugates for d targeting
	US5256641	1993-10	Yatvin et al.	State of Oregon	Covalent polar peptide conjugat immunological t
	US5258453	1993-11	Kopecek et al.	University of Utah	Drug delivery sy the simultaneou of drugs activat enzymes and lig
				State of Oregon, Acting by and Through the Oregon State	Covalent polar

 US5543389	1996-08	Yatvin et al.	Board of Higher Education on Behalf of the Oregon Health Sciences University, a non profit organization	<u>peptide conjugates in salves</u>
 US5543390	1996-08	Yatvin et al.	State of Oregon, Acting by and Through the Oregon State Board of Higher Education, Acting for and on Behalf of the Oregon Health Sciences University	<u>Covalent microp drug conjugates biological target</u>
 US5543391	1996-08	Yatvin et al.	State of Oregon, Acting by and Through the Oregon State Board of Higher Education, Acting for and on Behalf of the Oregon Health Sciences University	<u>Covalent microp drug conjugates biological target</u>
 US5840674	1998-11	Yatvin et al.	Oregon Health Sciences University	<u>Covalent microp drug conjugates biological target</u>

Foreign References:

Buy PDF	Publication	Date	IPC Code	Assignee	Title
 EP0077529	1983-04	C07C 93/187	Sanol Schwarz GmbH	<u>Medicinal form</u>	
 EP0109484	1983-04	G08B 21/00	Trampnau, Ulrich	<u>Warning device for helicopters</u>	
 EP0203676	1986-12	A61K 39/12	THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY	<u>Vaccine for generating immunogenic response protecting against a virus</u>	
 EP0279887	1988-08	C07C 101/30	Kesner, Leo	<u>Carnitine direct pharmaceuticals and their use for manufacture of medicament for treatment of metabolic disorder</u>	
 WO8911299	1989-11	A61K 49/00	STATE OF OREGON acting by and through THE STATE ...	<u>METHOD FOR DELIVERY OF THERAPEUTIC AGENTS TO TARGET B TISSUE USING MONOCLONAL ANTIBODY CONJUGATES</u>	
 WO8910348	1989-11	C07C 99/10	GIBBONS, William, Anthony	<u>FATTY AMINO ACID HOMO-ANALOGUE HETERO-OLIGOMERIC CONJUGATES THEREOF</u>	
 WO9000555	1990-01	C07H 15/12	VICAL, INC.	<u>LIPID DERIVATIVES ANTIVIRAL NUCLEOSIDE LIPOSOMAL INCORPORATION METHOD OF COVALENT CONJUGATES</u>	

 WO9010448	1990-09	A61K 31/70	GENENTECH, INC.	AND OLIGONUCLE
 WO9101750	1991-02	A61K 39/02	UNIVAX BIOLOGICS INCORPORATED	LIPID A ANALOG/IMM CARRIER CO AND THE USE AS VACCINES
 WO9116024	1991-10	A61F 13/00	VICAL, INC.	CATIONIC LIP INTRACELLU DELIVERY OF BIOLOGICALL MOLECULES
 WO9119726A	1991-12	C07H 17/00	KUCERA, Louis, S.	ETHER LIPID- NUCLEOSIDE COVALENT CONJUGATES
 WO9401131	1994-01	A61K 39/00	EUKARION, INC.	TRANSVASCU INTRACELLU DELIVERY OF PROTEINS
 WO9401138	1994-01	A61K 47/48	STATE OF OREGON, acting by and through the OREGON STATE BOARD OF HIGHER EDUCATION on behalf of the OREGON HEALTH SCIENCES UNIVERSITY	COVALENT P LIPID-PEPTID CONJUGATES BIOLOGICAL TARGETING
 WO9402178	1994-02	A61K 47/48	THE GOVERNMENT OF THE UNITED STATES OF AMERICA as	TARGETING O LIPOSOMES T BLOOD-BRAIN BARRIER
 WO9403424	1994-02	C07C 323/41	DRUG DELIVERY SYSTEM INSTITUTE, LTD.	COMPOUND OF INTRACER RESIDENCE A THEREOF
 WO9406450	1994-03	A61K 37/00	UNIVERSTIY OF FLORIDA	BRAIN-ENHAN DELIVERY OF NEUROACTIV PEPTIDES BY SEQUENTIAL METABOLISM
 WO9425616	1994-11	C12P 21/00	WORCESTER FOUNDATION FOR EXPERIMENTAL BIOLOGY	CELL-TARGE PORE-FORMI AGENTS
 WO9507092	1995-03	A61K 38/00	THE UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JE	BLOOD-BRAIN TRANSPORTE NEUROLOGIC AGENTS
 WO9522963	1995-08	A61K 9/51	MEDINOVA MEDICAL CONSULTING GMBH	DRUG TARGE SYSTEM, MET PREPARINGS ITS USE
 WO9532002	1995-11	A61K 47/48	STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE OREGON HEALTH	COVALENT MICROPARTI CONJUGATES BIOLOGICAL TARGETING

				SCIENCES UNIVERSITY	
	WO9604001	1996-02	A61K 38/00	MOLECULAR/STRUCTURAL BIOTECHNOLOGIES, INC.	SITE-SPECIFI BIOMOLECUL COMPLEXES
	WO9622303	1996-07	C07J 5/00	BENDER, Veronika, Judith	THERAPEUTI COMPOUND ACID CONJUG

Other Abstract Info: CHEMABS 118(04)027456V CHEMABS 120(24)307470P CHEMABS 124(14)185548E 125(16)204546S CHEMABS 125(18)230787R CHEMABS 129(25)335730C DERABS C 340298 DERABS C1993-350862 DERABS C1996-020359

Other References:

- Abbas et al., "Antigen Presentation and T Cell Antigen Recognition," *Cellular* as J. Mo (W.B. Saunders Co.; Philadelphia), pp. 116-136.
- Afzelius et al., *Biochim. Biophys. Acta* 979: 231-238 (1989).
- Alvarez-Domínguez et al., "Role of Complement Component C1q in Phagocytosis of *L* monocytogenes by Murine Macrophage-Like Cell Lines," *Infect. Immun.* 61:3664-3672 (1993).
- Anderson et al., *J. Am. Chem. Soc.* 85: 3039 (1963).
- Ashborn et al., "Anti-HIV Activity of CD4-Pseudomonas Exotoxin on Infected Primary Lymphocytes and Monocyte/Macrophages," *J. Infect. Dis.* 163: 703-709 (1991).
- Baer, *Can. J. Biochem. Phys.* 34: 288-304 (1955).
- Bai and Amidon, "Structural Specificity of Mucosal-Cell Transport and Metabolism of P Drugs: Implications for Oral Peptide Drug Delivery," *Pharm. Res.* 9: 969-978 (1992).
- Bai et al., "Utilization of Peptide Carrier System to Improve Intestinal Absorption: Targ Prolidase as a Prodrug-Converting Enzyme," *J. Pharm. Sci.* 81: 113-116 (1992).
- Barlow et al., "Mast cells and T lymphocytes in chronic urticaria," *Clinical & Experimental Allergy* 25: 317-322 (1995).
- Baroni et al., "Expression of HIV in Lymph Node Cells of LAS Patients: Immunohistochemical Hybridization, and Identification of Target Cells," *Am. J. Pathol.* 133: 498-506 (1988).
- Berdet et al., *Lipids* 22: 943-946 (1987).
- Bickel et al., "Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery," *Proc. Natl. Acad. Sci. USA* 90: 2618-2622 (1993).
- Blakey, "Drug Targeting with Monoclonal Antibodies," *Acta Oncol.* 31: 91-97 (1992).
- Blight et al., "Detection of hepatitis C virus RNA by in situ hybridization," *Liver* 12: 286.
- Blum et al., "Blood clearance and organ deposition of intravenously administered colloid particles: the effects of particle size, nature and shape," *Int. J. Pharm.* 12: 135-146 (1982).
- Boehnlein et al., "Characterization of Esterase and Alcohol Dehydrogenase Activity in Metabolism of Retinyl Palmitate to Retinol (Vitamin A) During Percutaneous Absorption," *Pharmaceutical Research* 11: 1155-1159 (1994).
- Boman et al., "Cell-free immunity in *Cecropia*: A model system for antibacterial protein," *Biochem.* 201: 23-31 (1990).
- Borissova et al., "Biodegradable Microspheres. 17. Lysosomal Degradation of Primärarm Spacer Arms," *Journal of Pharmaceutical Sciences*, vol. 84, No. 2, Feb. 1995, pp. 256-262.
- Bou-Gharios et al., "Expression of ectopeptidases in scleroderma," *Annals of Rheumatology Disease* 54: 1111-1116 (1995).
- Brewster et al., "Improved Delivery through Biological Membranes XXXI: Solubilization and Stabilization of an Estradiol Chemical Delivery System by Modified β -Cyclodextrins," *J. Pharm. Sci.* 77: 981-985 (1985).
- Bromberg et al., "Detection of *Bordetella pertussis* Associated with the Alveolar Macrophages in Children with Human Immunodeficiency Virus Infection," *Infect. Immun.* 59: 4715-4719 (1991).
- Brown & Silvius, *Biochim. Biophys. Acta* 1023: 341-351 (1990).
- Brown et al., "Induction of Cell Surface Peptidase Activity: A Global Response to Cell Death Correlated with Apoptosis," *J. Cellular Biochemistry* 54: 320-331 (1994).
- Brynestad et al., *J. Virol.* 64:680-685 (1990).

- Buchmeier and Heffron, "Induction of *Salmonella* Stress Proteins upon Infection of *Macrophages*," *Science* 248: 730-732 (1990).
- Buyuktimkin et al., "Synthesis and Enhancing Effect of Dodecyl 2-(N,N-Dimethylamino) on the Transepidermal Delivery of Indomethacin, Clonidine, and Hydrocortisone," *Pharm Research* 10: 1632-1637 (1993).
- Chang, "Leishmania donovani: Promastigote-Macrophage Surface Interactions in *Vitr* *Parasitol* 48:175-189 (1979).
- Clarke et al., "Detection of HIV-1 in human lung macrophages using the polymerase c reaction," *AIDS* 4: 1133-1136 (1990).
- Comiskey & Heath, *Biochim. Biophys. Acta* 1024: 307-317 (1990).
- Cordier et al., "In vivo Activation of Alveolar Macrophages in Ovine Lentivirus Infection," *Immunol. Immunopathol.* 55: 355-367 (1990).
- Couveur and Puisieux, "Nano-and microparticles for the delivery of polypeptides and *Adv. Drug Deliv. Rev.* 10: 141-162 (1993).
- Dachun et al., "Localization and Quantification of the Nonspecific Esterase in Injured Skin: Timing of Wounds," *Forensic Science International* 53: 203-213 (1992).
- De Magistris et al., "Antigen Analog-Major Histocompatibility Complexes Act As Antagonists of the T Cell Receptor," *Cell* 68: 625-634 (1992).
- Debs et al., *Biochim. Biophys. Acta* 901: 183-190 (1987).
- Deres et al., *Nature* 342:561-564 (1989).
- Dreyer et al., *Proc. Natl. Acad. Sci. USA* 86: 9752-9756 (1989).
- Duncan, "Drug-polymer conjugates: potential for improved chemotherapy," *Anticancer Res.* 12: 175-210 (1992).
- Elliott et al., "Naturally processed peptides," *Nature* 348: 195-197 (1990).
- Embretson et al., "Massive covert infection of helper T lymphocytes and macrophage during the incubation period of AIDS," *Nature* 362: 359-361 (1993).
- Falk et al., "Allele-specific motifs revealed by sequencing of self-peptides eluted from molecules," *Nature* 351: 290-291 (1991).
- Falk et al., "Cellular peptide composition governed by major histocompatibility complex molecules," *Nature* 348: 248-251 (1990).
- Faulk et al., "Transferrin-Adriamycin Conjugates which Inhibit Tumor Cell Proliferation: Interaction with DNA Inhibit Plasma Membrane Oxidoreductase and Proton Release in *K562* Cells," *Biochem. Int.* 25: 815-822 (1991).
- Faustman et al., "Linkage of Faulty Major Histocompatibility Complex Class I to Autoimmunity in *Diabetes*," *Science* 254: 1756-1776 (1991).
- Franssen et al., "Low Molecular Weight Proteins as Carrier for Renal Drug Targeting: of Drug-Protein Conjugates and Drug-Spacer Derivatives and Their Catabolism in Renal Homogenates and Lysosomal Lysates," *J. Med. Chem.* 35: 1246-1259 (1992).
- Frehel et al., "Intramacrophage Growth of *Mycobacterium avium* during Infection of *Mice*," *Immunol. Rev.* 150: 2207-2214 (1991).
- Friedman et al., "Uptake and Intracellular Survival of *Bordetella pertussis* in Human Macrophages," *Infect. Immun.* 60: 4578-4585 (1992).
- Frisch et al., "Parameters affecting the immunogenicity of a liposome-associated synthetic hexapeptide antigen," *Eur. J. Immunol.* 21: 185-193 (1991).
- Gaspar et al., "Drug targeting with polyalkylcyanoacrylate nanoparticles: in vitro activation of primaquine-loaded nanoparticles against intracellular *Leishmania donovani*," *Ann. Trop. Parasitol.* 86: 41-49 (1992).
- Gendelman et al., "Slow, persistent replication of lentiviruses: Role of tissue macrophages and macrophage precursors in bone marrow," *Proc. Natl. Acad. Sci. USA* 82: 7086-7090 (1985).
- Germain & Hendrix, "MHC class II structure, occupancy and surface expression determine post-endoplasmic reticulum antigen binding," *Nature* 353: 134-139 (1991).
- Groisman et al., "Resistance to host antimicrobial peptides is necessary for *Salmonella* infection," *Proc. Natl. Acad. Sci. USA* 89: 11939-11943 (1992).
- Guery et al., "Selective Immunosuppression by Administration of Major Histocompatibility Complex (MHC) Class II-binding Peptides. I. Evidence for In Vivo MHC Blockade Prevention of *Leishmania donovani* Infection," *Science* 260: 121-124 (1993).


Activation," *J. Exp. Med.* 175: 1345-1352 (1992).

- Halstead et al., "Dengue Viruses and Mononuclear Phagocytes: I. Infection Enhancement by Neutralizing Antibody," *J. Exp. Med.* 146:201-217 (1977).
- Hashimoto et al., *Biochim. Biophys. Acta* 816: 163-168 (1985).
- Hashimoto et al., *Biochim. Biophys. Acta* 816: 169-178 (1985).
- Heath and Martin, *Chem. Phys. Lipids* 40: 347-358 (1986).
- Heath et al., *Biochim. Biophys. Acta* 862: 72-80 (1986).
- Heath, *Methods in Enzymol.* 149: 111-119.
- Heinrich et al., "In-vivo Release of a GnRH Agonist from a Slow-release Poly(lactide-g Copolymer Preparation: Comparison in Rat, Rabbit and Guinea-Pig," *J. Pharm. Pharmacol.* 765 (1991).
- Henrikus and Kampffmeyer, "Ester hydrolysis conjugation reactions in intact skin and homogenate, and by liver esterase of rabbits," *Xenobiotica* 22: 1357-1366 (1992).
- Heymann et al., "Organophosphate Sensitive and Insensitive Carboxylesterases in Human Chem. Biol. Interactions
- Hopp, "Immunogenicity of a Synthetic HBsAg Peptide: Enhancement by Conjugation to an Acid Carrier," *Mol. Immunol.* 21: 13-16 (1984).
- Horwitz and Maxfield, "Legionella pneumophila Inhibits Acidification of its Phagosome in Monocytes," *J. Cell Biol.* 99: 1936-1943 (1984).
- Horwitz, "Interactions between Macrophages and Legionella pneumophila," *Curr. Top. Immunol.* 181:265-282 (1992).
- Horwitz, "The Legionnaires' Disease Bacterium (Legionella pneumophila) Inhibits Phagosome Lysosome Fusion in Human Monocytes," *J. Exp. Med.* 158: 2108-2126 (1983).
- Hostetler et al., *J. Biol. Chem.* 265: 6112-6117 (1990).
- Hunter et al., "Vesicular Systems (Niosomes and Liposomes) for Delivery of Sodium Stibogluconate in Experimental Murine Visceral Leishmaniasis," *J. Pharm. Pharmacol.* 40 (1988).
- Jacobson et al., *FEBS Lett.* 225: 97-102 (1987).
- Jardetzky et al., "Identification of self peptides bound to purified HLA-B27," *Nature* 35 (1991).
- Jones and Hirsch, "The Interaction between Toxoplasma gondii and Mammalian Cells," *Med.*, 136:1173-1194 (1972).
- Kanno et al., "Aleutian Mink Disease Parvovirus Infection of Mink Peritoneal Macrophages and Human Macrophage Cell Lines," *J. Virol.* 67:2075-2082.
- Kanno et al., "Identification of Aleutian Mink Disease Parvovirus Transcripts in Macroparasites Infected Adult Mink," *J. Virol.* 66:5305-5312 (1992).
- King et al., "In Vivo Selection of Lymphocyte-Tropic and Macrophage-Tropic Variants of Lymphocytic Choriomeningitis Virus during Persistent Infection," *J. Virol.* 64: 5611-5616 (1990).
- Kinsky & Loeder, *Biochim. Biophys. Acta* 921: 96-103 (1987).
- Kinsky et al., *Biochim. Biophys. Acta* 885: 129-135 (1986).
- Kinsky et al., *Biochim. Biophys. Acta* 917: 211-218 (1987).
- Kishimoto, *Chem. Phys. Lipids* 15: 33-36 (1975).
- Koenig et al., "Detection of AIDS Virus in Macrophages in Brain Tissue from AIDS Patients," *Science* 233: 1089-1093 (1986).
- Kondo et al., "Latent human herpesvirus 6 infection of human monocytes/macrophage," *J. Virol.* 72: 1401-1408 (1991).
- Koval & Pagano, "Lipid Recycling between the Plasma Membrane and Intracellular Compartments: Transport and Metabolism of Fluorescent Sphingomyelin Analogs in C3H10T1/2 Fibroblasts," *J. Cell Biol.* 108: 2169-2181 (1989).
- Kratz et al., "Keratinocyte conditioned medium stimulates type IV collagenase synthesis in cultured human keratinocytes and fibroblasts," *Brit. J. Dermatology* 133: 842-846 (1995).
- Kreeger, *The Scientist*, Sep. 16, 1996, p. 6.
- Krowka et al., *J. Immunol.* 144: 2535-2540 (1990).
- Kubota et al., "Metabolism and Degradation of Betamethasone 17-Valerate in Homograft Living Skin Equivalent," *Dermatology* 188: 13-17 (1994).

- Kung and Redemann, *Biochim. Biophys. Acta* 862: 435-439 (1986).
- Lamont et al., "The use of Peptide Analogs with Improved Stability and MHC Binding Inhibit Antigen Presentation In Vitro and In Vivo," *J. Immunol.* 144: 2493-2498 (1990).
- Lanzavecchia et al., "Irreversible association of peptides with class II MHC molecules cells," *Nature* 357: 249-252 (1992).
- Larsen et al., "Stability of ketoprofen-dextran ester prodrugs in homogenates of various of the pig GI tract," *Acta Pharm. Nord.* 3: 41-44 (1991).
- Lee et al., "Antibacterial peptides from pig intestines: Isolation of a mammalian cecropin," *Natl. Acad. Sci. USA* 86: 9159-9162 (1989).
- Lehninger, *Biochemistry*, 2d ed., Chapters 11 & 24, Worth Publishers: New York, 1973.
- Lehrer et al., "Defensins: Endogenous Antibiotic Peptides of Animal Cells," *Cell* 64: 22 (1991).
- Lin et al., "Preparation of Enteric-Coated Microspheres of mycoplasma hyopneumoniae cellulose acetate; (ii) effect of temperature and pH on the stability and release behaviour of microspheres," *Journal of Microencapsulation*, vol. 8, No. 4: 537-545 (1991).
- Lipozencic et al., "Langerhans cells in the immunopathology of contact allergic dermatitis," *Histochem* 38: 303-310 (1994).
- Loughery et al., *J. Immunol. Methods* 132: 25-35 (1990).
- MacDonald, *J. Biol. Chem.* 265: 13533-13539 (1990).
- Maciejewski et al., "Infection of Mononucleated Phagocytes with Human Cytomegalovirus," *Nature* 365: 327-336 (1993).
- Matsura et al., *J. Chem. Soc. Chem. Comm.* xx: 451-459 (1976).
- Mauel et al., "Quantitative Release of Live Micro-organisms from Infected Macrophages by Sodium Dodecyl Sulfate," *Nature New Biol.* 244:93-94 (1973).
- Mauel, "Macrophage-Parasite Interactions in Leishmania Infections," *J. Leukocyte Bio* 193 (1990).
- McEntee et al., "Rhesus monkey macrophages infected with simian immunodeficiency virus cause rapid lysis of CD4-bearing lymphocytes," *J. Gen. Virol.* 72: 317-324 (1991).
- Meltzer and Gendelman, "Mononuclear Phagocytes as Targets, Tissue Reservoirs, and Immunoregulatory Cells in Human Immunodeficiency Virus Disease," *Curr. Topics Microbiol. Immunol.* 181: 239-263 (1992).
- Menger et al., "Synthesis of a Lipid/Peptide/Drug Conjugate: N4-(Acylpeptidyl)-ARA-C Bioconjugate Chemistry 5: 162-166 (1994).
- Moehrle et al., "Aminopeptidase M and dipeptidyl peptidase IV activity in epithelial skin histological study," *J. Cutaneous Pathology* 22: 241-247 (1995).
- Mukherjee & Heidelberger, *Cancer Res.* 22: 815-822 (1962).
- Murray et al., "Experimental Visceral Leishmaniasis: Production of Interleukin 2 and In Tissue Immune Reaction, and Response to Treatment with Interleukin 2 and Interferon gamma," *Immunol.* 138: 2290-2296 (1987).
- Narayan et al., "Lentivirus Induced Arthritis in Animals," *J. Rheumatol.* 32:25-32 (1992).
- Negre et al., "Antileishmanial Drug Targeting through Glycosylated Polymers Specific Internalized by Macrophage Membrane Lectins," *Antimicrob. Agents and Chemother.* 36 (1992).
- Neto et al., *Biochem. Biophys. Res. Commun.* 171: 458-464 (1990).
- Ng & Heath, *Biochim. Biophys. Acta* 981: 261-268 (1989).
- Nogueira and Cohn, "Trypanosoma cruzi: Mechanisms of Entry and Intracellular Fate in Mammalian Cells," *J. Exp. Med.* 143:1402-1420 (1976).
- Nothnagel, *Biochim. Biophys. Acta* 980: 209-219 (1989).
- Pagano et al., *J. Biol. Chem.* 258: 2034-2040 (1983).
- Panuska et al., "Productive Infection of Isolated Human Alveolar Macrophages by Respiratory Syncytial Virus," *J. Clin. Invest.* 86: 113-119 (1990).
- Pardridge, "Opioid Peptide Drug Development: Transport of Opioid Chimeric Peptides across the Blood-Brain Barrier," *NIDA Res. Monograph* 120: 153-168 (1992).
- Parham, "Transporters of delight," *Nature* 348: 674-675 (1990).
- Paul and Anderson, *J. Am. Chem. Soc.* 82: 4596-4600 (1960).

- Payne et al., "Phagocytosis of *Legionella pneumophila* is Mediated by Human Monoc Complement Receptors," *J. Exp. Med.* 166: 1377-1389 (1987).
- Rahman et al., *Life Sci.* 31: 2061-2071 (1982).
- Remy et al., *J. Org. Chem.* 27: 2491-2500 (1962).
- Rosenberg et al., *J. Neurochem.* 48: 865-875 (1987).
- Rowlinson-Busza and Epenetos, "Targeted delivery of biologic and other antineoplast *Curr. Opin. Oncol.* 4: 1142-1148 (1992).
- Rubinstein et al., "In Vitro Evaluation of Calcium Pectinate: A Potential Colon-Specific Delivery Carrier," *Pharm. Res.* 10: 258-263 (1993).
- Sadegh-Nasseri and Germain, "A role for peptide in determining MHC class II structur *353*: 167-170 (1991).
- Saffran et al., "A New Approach to the Oral Administration of Insulin and Other Peptid *Science* 233: 1081-1084 (1986).
- Salord et al., *Biochim. Biophys. Acta* 886: 64-75 (1986).
- Schlessinger and Horwitz, "Phagocytosis of Leprosy Bacilli is Mediated by Compleme Receptors CR1 and CR3 on Human Monocytes and Complement Component C3 in Ser *Invest.* 85: 1304-1314 (1990).
- Schmitt et al., "Multiplication of Human Immunodeficiency Virus in Primary Cultures o Kupffer Cells—Possible Role of Liver Macrophage Infection in the Physiopathology of AID *Virol.* 141: 143-152 (1990).
- Schnorr et al., "MxA-Dependent Inhibition of Measles Virus Glycoprotein Synthesis in Transfected Human Monocytic Cell Line," *J. Virol.* 67: 4760-4768 (1993).
- Seifert et al., *Biochem. J.* 267:795-802 (1990).
- Sellon et al., "Wild-Type Equine Infectious Anemia Virus Replicates in Vivo Predomin Tissue Macrophages, Not in Peripheral Blood Monocytes," *J. Virol.* 66: 5906-5913 (1992).
- Senter et al., "Activation of Prodrugs by Antibody-Enzyme Conjugates," in *Immunobio Peptides and Proteins*, vol. VI, pp. 97-105 (1991).
- Shanley and Pesanti, "Murine Peritoneal Macrophages Support Murine Cytomegalovi Replication," *Infect. Immunol.* 41: 1352-1359 (1983).
- Shen et al., "Cis-Aconityl Spacer between Daunomycin and Macromolecular Carriers: pH Sensitive Linkage Releasing Drug from a Lysomotropic Conjugate," *Biochem. Biophys Commun.* 102:1048-1052 (1981).
- Sierra-Honigman et al., "Borna disease virus in peripheral blood mononuclear and bo cells of neonatally and chronically infected rats," *J. Neuroimmunol.* 45: 31-36 (1993).
- Sintov et al., "Enzymatic cleavage of disaccharaide side groups in insoluble synthetic new method for specific delivery of drugs to the colon," *Biomaterials* 14: 483-490 (1993).
- SivaSai et al., "Effect of Recombinant Interferon Gamma Administration on Lesional Monocytes/Macrophages in Lepromatous Leprosy Patients," *Int. J. Leprosy & Other Myc Diseases* 61: 259-269 (1993).
- Small, "From alkanes to phospholipids," *Handbook of Lipid Research: Physical Chem Lipids*, vol. 4, Chapters 4 and 12, Plenum Press: New York, 1986.
- Smith and Khorana, *J. Amer. Chem. Soc.* 80: 1141-1145 (1958).
- Steim et al., *Biochem. Biophys. Res. Commun.* 171: 451-457 (1990).
- Strellrecht-Broomhall, "Evidence for Immune-Mediated Destruction as Mechanism for Induced Anemia in Persistently Infected Mice," *Viral Immunol.* 4: 269-280 (1991).
- Sturgill-Koszycki et al., "Lack of Acidification in *Mycobacterium* Phagosomes Produce Exclusion of the Vesicular Proton-ATPase," *Science* 263: 678-681 (1994).
- Trouet et al., "A covalent linkage between daunorubicin and proteins that is stable in s reversible by lysosomal hydrolases, as required for a lysomotropic drug-carrier conjugate and in vivo studies," *Proc. Natl. Acad. Sci. USA* 79:626-629 (1982).
- van Wijk et al., *Biochim. Biophys. Acta* 1084: 307-310 (1991).
- Vandebark et al., *Nature* 341:841-844 (1989).
- Verbloom et al., *Synthesis* 1032: 807-809 (1981).
- Wada et al., "Salt Formation of Lactic Acid Oligomers as Matrix for Sustained Release *J. Pharm. Pharmacol.* 43: 605-608 (1991).


- Wiesmuller et al., "The antibody response in BALB/c mice to the Plasmodium falcipar circumsporozoite repetitive epitope covalently coupled to synthetic lipopeptide adjuvant," 109-113 (1991).
- Wyrick and Brownridge, "Growth of Chlamydia psittaci in Macrophages," Infect. Immu 19:1054-1060 (1978).
- Yatvin et al., "Targeting Lipophilic Prodrugs to Brain, Lung, and Spleen," Journal of Ce Biochemistry, vol. 0, No. 19A: 173 (1995).
- Yatvin, "A Multi-Modality Approach for the Treatment of AIDS," Select. Cancer. Thera 28 (1991).
- Zasloff, "Magainins, a class of antimicrobial peptides from Xenopus skin: Isolation, characterization of two active forms, and partial cDNA sequence of a precursor," Proc. N Sci USA 84: 5449-5453 (1987).
- Zhang and McCormick, "Uptake of N-(4'-pyridoxyl)amines and release of amines by re model for transporter-enhanced delivery of bioactive compounds," Proc. Natl. Acad. Sci. 10407-10410 (1991).



Nominate this for the Galle

© 1997-2003 Thomson Delphion [Research Subscriptions](#) | [Privacy Policy](#) | [Terms & Conditions](#) | [Site Map](#) | [Contact Us](#) | [Help](#)

Home **R&D** **Press Releases** **Info** **Publications** **Contact**



Entrez PubMed Nucleotide Protein Genome Structure PMC Journals Bo

Search

for Limits Preview/Index History Clipboard Details

About Entrez

[Text Version](#)

[Entrez PubMed](#)

[Overview](#)

[Help | FAQ](#)

[Tutorial](#)

[New/Noteworthy](#)

[E-Utilities](#)

[PubMed Services](#)

[Journals Database](#)

[MeSH Database](#)

[Single Citation Matcher](#)

[Batch Citation Matcher](#)

[Clinical Queries](#)

[LinkOut](#)

[Cubby](#)

[Related Resources](#)

[Order Documents](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

[Privacy Policy](#)

Show:

1: J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Mar 1;14 (3):193-203. [Related Art](#) [L](#)

A lipidated anti-Tat antibody enters living cells and blocks HIV-viral replication.

Cruikshank WW, Doctrow SR, Falvo MS, Huffman K, Maciaszek J, Viglianti G, Raina J, Kornfeld H, Malfroy B.

Pulmonary Center, Boston University School of Medicine, Massachusetts, U.S.A.

We have developed a chemical modification of antibodies, lipidation, which enables their intracellular delivery into living cells. Intracellular localization of lipidated antibodies was demonstrated by confocal microscopy and by measuring cellular uptake of ¹²⁵I-labeled lipidated antibodies. Functionally, lipidated monoclonal antibody directed against the Tat protein from human immunodeficiency virus type 1 (HIV-1) inhibited viral replication of several HIV-1 isolates by approximately 85% as shown by increased viability of infected cells and decreased reverse transcriptase activity. The antibody in its native form had no such effect. These data show that lipidated antibodies can reach and functionally inhibit intracellular targets. Lipidation may help to facilitate the development of intracellular immunotherapy for AIDS.

PMID: 9117450 [PubMed - indexed for MEDLINE]

Show:

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)

Dec 1 2003 07

Eukarion, Inc.
6F Alfred Circle
Bedford, MA 01730
Phone (781) 275-0424
Fax (781) 275-0752
www.eukarion.com

NEWS RELEASE

Contact:

Dr. Bernard Malfroy, CEO
781-275-0424

HIV VIRAL REPLICATION IN LIVING CELLS BLOCKED USING EUKARION ANTIBODY LIPIDATION TECHNOLOGY

(Bedford, MA, April 14, 1997) -- Eukarion, Inc. today announced that it has successfully blocked HIV-1 viral replication in living cells using a monoclonal antibody chemically modified to permit passage across cell membranes. A paper describing these results was published in the March issue of the *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology*.

"These findings are important for two reasons," said Bernard Malfroy, Ph.D., Eukarion's chief executive officer. "First, since HIV multiplies rapidly within cells, an approach to halting viral replication could contribute to the development of cell-specific AIDS immunotherapies." The Eukarion antibody targets the HIV-1 "Tat" protein that is required for HIV viral replication. In laboratory experiments using a human lymphocytic cell line, the modified (lipidated) anti-Tat antibody accumulated in HIV-1 infected cells. Once entering the infected cells, the lipidated anti-Tat antibody bound to the Tat protein and blocked its function, leading to suppressed viral replication and, concomitantly, to greatly improved cell survival. The lipidated anti-Tat antibody was found to be effective not only against a laboratory strain of HIV-1, but also against three strains of virus isolated from patients.

"Second and more broadly, we have demonstrated that Eukarion's lipidation technology can facilitate the delivery of antibodies to intracellular targets and that the antibodies retain their binding

specificity and activity," Dr. Malfroy said. "Most monoclonal antibody-based products in development today bind to sites on cell surfaces. With lipidation, we can now use antibodies to target disease-causing substances inside cells and significantly expand the use of monoclonal antibodies for the treatment of human diseases." Eukarion is also evaluating the use of its lipidation technology for other therapeutic applications, and for use with proteins other than antibodies.

The journal article was authored by William W. Cruikshank, Susan R. Doctrow, Melissa S. Falvo, Hardy Kornfeld, Karl Huffmann, Jay Raina and Dr. Malfroy. It represents a collaborative effort between researchers at Eukarion and the Boston University School of Medicine. Dr. Cruikshank, who is Associate Professor of Medicine, directed the principal studies in his laboratory at the B.U. Pulmonary Center.

In addition to its lipidation program, Eukarion has a separate effort underway to develop synthetic catalytic scavenger (SCS) compounds to target reactive oxygen intermediates (ROIs), toxic by-products of tissue stress. ROIs have been implicated in the irreversible damage that occurs in patients suffering from many chronic disorders including asthma, atherosclerosis, lupus, multiple sclerosis, neurodegenerative diseases of the central nervous system, ischemia-induced organ damage, allergy and adult respiratory distress syndrome. These seemingly diverse conditions appear to have ROI involvement as a common link, creating the potential for a small number of SCS compounds to address huge unmet medical needs.

In February 1997, Eukarion signed an agreement with Glaxo Wellcome plc, the world's largest research based pharmaceutical company, for a three year collaborative research and development program for the Eukarion SCS program. The agreement will provide Eukarion scientists with access to Glaxo Wellcome's substantial R&D and screening capabilities and will allow Eukarion to operate at break-even financial levels for the foreseeable future.

Eukarion, Inc., located in Bedford, MA, is a privately held company formed in 1991 to develop proprietary compounds directed against intracellular targets for the treatment of human disease. Eukarion's technologies are protected by issued and pending patent applications owned by the company.



| [home](#) | [r&d](#) | [press releases](#) | [info](#) | [publications](#) | [contact](#) |

contact : mail@eukarion.com